MedTrace Logo

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

NCT05441488 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2026-05-06

No results posted yet for this study

Summary

To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.

Conditions

Interventions

DRUG

Placebo

treatment per os

DRUG

Masitinib (4.5)

Masitinib (titration to 4.5 mg/kg/day)

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Patrick VERMERSCH, MD, PhD · University of Lille, CHU of Lille, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-28
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • France
  • Greece
  • Italy
  • Poland
  • Russia
  • Spain
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05441488 on ClinicalTrials.gov